Related Experiment Video
Updated: Apr 6, 2026
09:24
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
Published on: August 12, 2015
9.7K
Blocking Cancer Growth with Less POMP or Proteasomes
Alfred L Goldberg1, Jinghui Zhao1, Galen A Collins1
1Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
Molecular Cell
|July 18, 2015
Summary
MicroRNA-101 (miR-101) regulates proteasome levels by targeting the POMP chaperone. Loss of miR-101 in some cancers increases proteasome content, impacting cell regulation and cancer therapy.
Area of Science:
- Molecular Biology
- Cell Biology
- Cancer Research
Background:
- Proteasomes are crucial for cellular regulation and cancer treatment.
- Factors controlling proteasome abundance and activity remain largely unknown.
- Understanding proteasome regulation is vital for therapeutic advancements.
Purpose of the Study:
- To investigate the role of microRNA-101 (miR-101) in regulating proteasome content.
- To identify the specific targets of miR-101 within the proteasome assembly pathway.
- To explore the implications of miR-101 dysregulation in cancer.
Main Methods:
- Utilized molecular biology techniques to study gene expression.
- Investigated the interaction between miR-101 and its target genes.
- Analyzed proteasome content in cancer cells with varying miR-101 levels.
Main Results:
- miR-101 was found to suppress the expression of the proteasome chaperone POMP.
- miR-101 also affects the assembly of the 20S proteasome core.
- Certain cancers exhibit reduced miR-101 levels, correlating with increased proteasome content.
Conclusions:
- miR-101 acts as a negative regulator of proteasome biogenesis.
- Loss of miR-101 contributes to elevated proteasome levels in specific cancers.
- These findings offer insights into proteasome regulation and potential therapeutic strategies for cancer.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
01:23Negative Regulator Molecules
39.0K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
39.0K
02:23Abnormal Proliferation
5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
03:03mTOR Signaling and Cancer Progression
5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.1K
03:03mTOR Signaling and Cancer Progression
1.7K
1.7K
02:50Combination Therapies and Personalized Medicine
6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K